

# Hematopoietic Cell-Specific Deletion of Toll-like Receptor 4 Ameliorates Hepatic and Adipose Tissue Insulin Resistance in High-Fat-Fed Mice

Maziyar Saberi,<sup>1,3</sup> Niels-Bjarne Woods,<sup>2,3</sup> Carl de Luca,<sup>1</sup> Simon Schenk,<sup>1</sup> Juu Chin Lu,<sup>1</sup> Gautam Bandyopadhyay,<sup>1</sup> Inder M. Verma,<sup>2</sup> and Jerrold M. Olefsky<sup>1,\*</sup>

<sup>1</sup>Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, La Jolla, CA 92093, USA

<sup>2</sup>The Salk Institute for Biological Studies, La Jolla, CA 92037, USA

<sup>3</sup>These authors contributed equally to this work

\*Correspondence: [jolefsky@ucsd.edu](mailto:jolefsky@ucsd.edu)

DOI 10.1016/j.cmet.2009.09.006

## SUMMARY

Chronic low-grade inflammation, particularly in adipose tissue, is an important modulator of obesity-induced insulin resistance. The Toll-like receptor 4 (Tlr4) is a key initiator of inflammatory responses in macrophages. We performed bone marrow transplantation (BMT) of Tlr4<sup>lps-del</sup> or control C57Bl/10J donor cells into irradiated wild-type C57Bl/6 recipient mice to generate hematopoietic cell-specific Tlr4 deletion mutant (BMT-Tlr4<sup>-/-</sup>) and control (BMT-WT) mice. After 16 weeks of a high-fat diet (HFD), BMT-WT mice developed obesity, hyperinsulinemia, glucose intolerance, and insulin resistance. In contrast, BMT-Tlr4<sup>-/-</sup> mice became obese but did not develop fasting hyperinsulinemia and had improved hepatic and adipose insulin sensitivity during euglycemic clamp studies, compared to HFD BMT-WT controls. HFD BMT-Tlr4<sup>-/-</sup> mice also showed markedly reduced adipose tissue inflammatory markers and macrophage content. In summary, our results indicate that Tlr4 signaling in hematopoietic-derived cells is important for the development of hepatic and adipose tissue insulin resistance in obese mice.

## INTRODUCTION

Insulin resistance is a major metabolic defect in obesity and is associated with increased risk of various diseases, such as type 2 diabetes, hypertension, and coronary heart disease (Facchini et al., 2001). In recent years, chronic, low-grade inflammation has emerged as an important contributor to the etiology of insulin resistance in obesity, and because the expansion of adipose tissue mass is an obvious corollary of obesity, much research has focused on adipose tissue as a potential site of this inflammation. Indeed, obese adipose tissue is characterized by increased expression of inflammatory genes, such as tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL)-6, regulated upon activation normal T cell expressed and secreted (RANTES), and monocyte chemoattractant protein (MCP)-1, as well as increased infiltration by immune cells, particularly macrophages (Nguyen

et al., 2007; Weisberg et al., 2003; Xu et al., 2003). Macrophages are an important modulator of inflammation through their capacity to secrete a variety of proinflammatory chemokines and cytokines. In fact, adipose tissue macrophages (ATMs) appear to be responsible for much of the increase in inflammation in adipose tissue with obesity (Weisberg et al., 2003; Xu et al., 2003). Consistent with a role for macrophages and inflammation in the pathogenesis of insulin resistance, we have recently shown that deletion of the two primary inflammatory pathways in macrophages, namely the inhibitor of  $\kappa$ B kinase/nuclear factor  $\kappa$ B (IKK/NF $\kappa$ B) (Arkan et al., 2005) and c-Jun NH<sub>2</sub> terminal kinase 1/activator protein (JNK1/AP1) (Solinas et al., 2007) pathways, attenuates obesity-induced insulin resistance. Thus, preventing the propagation of inflammatory signals within macrophages is sufficient to mitigate obesity-induced insulin resistance. Nonetheless, the upstream components or pathways that detect, initiate, and activate the proinflammatory IKK/NF $\kappa$ B and JNK/AP1 pathways remain to be fully elucidated.

The “sensors” that potentially link obesity to inflammation are the Toll-like family of receptors (Tlrs); Tlrs are pattern recognition receptors that play critical roles in innate immunity (Aderem and Ulevitch, 2000; Wolowczuk et al., 2008). Relevant to obesity and inflammation, Tlrs, particularly Tlr2 and Tlr4, are highly expressed in macrophages and adipose tissue. Indeed, we (Nguyen et al., 2007) and others (Lee et al., 2001, 2003) have shown that fatty acids (particularly saturated fatty acids) can activate Tlr2/4, resulting in activation of the IKK/NF $\kappa$ B and JNK1 pathways, with enhanced secretion of proinflammatory chemokines and cytokines (e.g., TNF- $\alpha$ ). In contrast, in vitro fatty acid-induced activation of JNK and IKK or induction of proinflammatory cytokine expression or secretion is prevented by small interfering RNA (siRNA)-mediated knockdown of Tlr2/4 in the RAW264.7 macrophage cell line or in macrophages from Tlr4 knockout mice (Nguyen et al., 2007; Shi et al., 2006).

Because obesity is characterized by elevated fatty acid levels (Horowitz et al., 1999; Jensen et al., 1989), the fact that fatty acids can stimulate a receptor that activates inflammatory pathways provides a potentially important link between obesity, inflammation, and insulin resistance. In support of this, Tlr4 expression is increased in adipose tissue in obesity and in proinflammatory macrophages (Nguyen et al., 2007; Shi et al., 2006). In addition, obesity due to high-fat diet (HFD) feeding and insulin resistance caused by a lipid-plus-heparin infusion were

attenuated in Tlr4 knockout mice, in parallel with decreased inflammation in both liver and adipose tissue (Shi et al., 2006; Tsukumo et al., 2007). However, although these studies clearly implicate Tlr4 in the development of lipid and obesity-induced insulin resistance, the specific tissue(s) in which Tlr4 depletion works to protect mice from insulin resistance remains to be defined.

Considering the clear role of macrophages in the propagation of inflammatory signals in adipose tissue and liver (i.e., through the liver-specific macrophage cell type, the Kupffer cell), we hypothesized that knockout of Tlr4 signaling in hematopoietic-derived cells (which includes macrophages) would reduce obesity-related increases in macrophage infiltration and inflammation and subsequently prevent in vivo insulin resistance. To address this hypothesis, we generated mice with Tlr4 deleted exclusively in hematopoietic cells. Our results reveal that mice deficient in Tlr4 in their hematopoietic compartment are protected from HFD and obesity-induced insulin resistance, in parallel with reduced macrophage infiltration in adipose tissue, reduced chemokine and lymphokine secretion, and a marked reduction in inflammation in adipose and liver.

## RESULTS

### Hematopoietic Deletion of Tlr4 Does Affect Peripheral Lineage Distributions

To generate mice with a complete knockout of Tlr4 in macrophages and other immune cells, we transplanted irradiated wild-type (WT) C57BL/6 mice with bone marrow from Tlr4<sup>lps-del</sup> (Poltorak et al., 1998) or WT C57BL/10J mice. This adoptive transfer approach yielded chimeric mice that were deficient in Tlr4 (BMT-Tlr4<sup>-/-</sup>) in all hematopoietic-derived cells but that had normal Tlr4 expression in all nonhematopoietic tissues such as skeletal muscle, liver, and adipose tissue. Using this technique, 8 weeks following bone marrow transplantation (BMT), > 95% of white blood cells from BMT-Tlr4<sup>-/-</sup> mice lacked Tlr4 (Figure 1A). Mice transplanted with bone marrow from wild-type C57BL/10J mice (BMT-WT) displayed normal Tlr4 expression in all hematopoietic-derived cells and nonhematopoietic cells/tissues. The loss of Tlr4 did not alter hematopoietic cell lineage distribution because monocyte, lymphocyte, and neutrophil counts were normal in the BMT-Tlr4<sup>-/-</sup> and BMT-WT mice (Figures 1B and 1C), though the proportions of the three cell types differed slightly between normal chow diet (NCD) and HFD-fed mice.

### Tlr4 Deletion Ameliorates Obesity-Induced Hyperinsulinemia

As expected, body weight gain in mice fed HFD significantly outpaced mice fed NCD. There were no significant body weight differences between BMT-WT or BMT-Tlr4<sup>-/-</sup> mice, and no differences in food intake were detected (Figures 1D–1G). In vivo volumetric analysis of body composition using magnetic resonance imaging (MRI) revealed a comparable increase in visceral and subcutaneous adipose deposition in HFD versus NCD mice, irrespective of BMT donor type cells (Figure 1G). These results demonstrate that the loss of Tlr4 did not affect the ability of the BMT mice to become obese; moreover, it did not affect the distribution of fat in the obese animal (Figure 1H).


The percent of weight gain on HFD is nearly identical in the WT versus the Tlr4<sup>-/-</sup> BMT groups, as is the absolute body weight gain (9.2 versus 9.0 g, BMT Tlr4<sup>-/-</sup> versus the BMT WT mice). Because the BMT-Tlr4<sup>-/-</sup> group started at a slightly lower weight (29.4 ± 1.1 versus 31.3 ± 1.4 g), the absolute body weight at the end of the 12 week period is slightly (1.7 g) less in the BMT-Tlr4<sup>-/-</sup> mice. Thus, the BMT-WT and BMT-Tlr4<sup>-/-</sup> groups are well matched for body weight, obesity, and all other aspects of adiposity. In contrast, on HFD, body weight gain was markedly reduced in the global Tlr4 knockout mice (i.e., nontransplanted mice with knockout of Tlr4 in all tissues) compared to WT controls (Figure 1I). Absolute body weights were 29.3 ± 0.6 versus 28.2 ± 0.7 at week 0 and 32.1 ± 0.9 versus 36.0 ± 0.8 at week 6, for a weight gain of 2.8 versus 7.8 g in the Tlr4<sup>-/-</sup> versus WT, respectively. These findings are comparable to the results of Tsukumo et al. (2007).

The glucose response during a glucose tolerance test (GTT) was increased in HFD-fed mice, and there were no statistical differences between the BMT-WT and BMT-Tlr4<sup>-/-</sup> mice (Figure 2A). On HFD, mice become hyperinsulinemic, but the insulin response during the GTT was significantly lower in HFD BMT-Tlr4<sup>-/-</sup> versus BMT-WT mice (Figures 2B and 2C), indicating an overall improvement in insulin action as a result of Tlr4 deletion from hematopoietic cells. Because both groups remain glucose intolerant, there must be a functional  $\beta$  cell defect in both, but we did not perform further islet studies. We next performed an insulin tolerance test (ITT), which shows that, whereas HFD caused insulin resistance in BMT-WT mice, the hypoglycemic response in the HFD BMT-Tlr4<sup>-/-</sup> group was comparable to NCD-fed mice (Figure 2D), directly demonstrating protection from insulin resistance in these mice. Thus, the deleterious effects of HFD/obesity on glucose metabolism and insulin sensitivity were significantly improved in HFD BMT-Tlr4<sup>-/-</sup> mice, suggesting that Tlr4 in immune cells plays an important role in mediating the effects of obesity on insulin action.

### Tlr4 Deletion Improves Peripheral Insulin Sensitivity

To further quantify whole-body insulin sensitivity and to better delineate the tissue-specific site(s) responsible for the improved glucose homeostasis in BMT-Tlr4<sup>-/-</sup> mice, we performed hyperinsulinemic-euglycemic clamp studies. With this procedure, we measured the rate of glucose infusion (GINF) that is required to keep a constant level of blood glucose during a simultaneous infusion of insulin; the higher the GINF, the greater the overall insulin sensitivity. The clamp results showed that the GINF that is required to maintain euglycemia (~125 mg/dl) was not significantly different between NCD-fed BMT-WT and BMT-Tlr4<sup>-/-</sup> mice. As expected, BMT-WT mice fed HFD had markedly decreased GINF values, confirming insulin resistance. In contrast, GINF values were ~70% higher in the HFD BMT-Tlr4<sup>-/-</sup> mice compared to BMT-WT (Figure 3A), demonstrating partial protection from HFD-induced insulin resistance. During the clamp studies, the steady-state insulin and glucose concentrations were the same between groups.

To determine the contribution of hepatic glucose production, a simultaneous infusion of tracer-labeled glucose was infused to provide a measure of the rate of glucose disposal (Rd). Subtracting the GINF from the total Rd yields the endogenous glucose production rate (mainly from liver). As compared to



**Figure 1. Hematopoietic Homeostasis Is Maintained in Mice following Bone Marrow Transplantation of Tlr4-Deleted Hematopoietic Cells**

(A) Real-time PCR analysis for the WT Tlr4 genomic locus in peripheral blood mononuclear cells from transplanted mice, demonstrating near complete reconstitution of white blood cells in bone marrow transplant recipient mice with Tlr4 deletion mutant hematopoietic cells (BMT-Tlr4<sup>-/-</sup>) (n = 8).

(B and C) Hematogram analyses demonstrating normal blood cell lineage distributions, including monocytes, lymphocytes, and neutrophils, in mice (BMT-Tlr4<sup>-/-</sup>), as compared with control mice transplanted with WT Tlr4 (BMT-WT) cells. HFD-fed mice had slightly altered lineage distributions with slightly increased neutrophil counts and decreased lymphocyte counts, but this was similar for both the BMT-WT and BMT-Tlr4<sup>-/-</sup> mice.


(D–F) Weight gain of mice given HFD or NCD over 12 weeks following BMT, with no statistical difference in weight gain or food intake/day between BMT-Tlr4<sup>-/-</sup> and BMT-WT mice.

(G and H) Cross section and coronal section views using 3D magnetic resonance imaging (MRI) of mice and software-based analyses of tissue volumes to determine the total weight of abdominal adipose tissues and subcutaneous fat tissues demonstrating similar distribution of adipose tissue in the BMT-WT and BMT-Tlr4<sup>-/-</sup> mice. Red arrows signify visceral fat, and yellow dots signify hepatic tissue.

(I) Weight gain results of a control experiment in which the global Tlr4 knockout mice and WT mice were placed on HFD. No weight gain was seen in the global Tlr4 knockout mice on a HFD.

NCD mice, HFD BMT-WT mice displayed increased basal hepatic glucose production (HGP) with a markedly impaired ability of insulin to suppress HGP during the clamp (Figures 3B and 3C), demonstrating hepatic insulin resistance. In contrast, in HFD BMT-Tlr4<sup>-/-</sup> mice, basal HGP and insulin suppression of HGP was completely normalized to values seen in NCD mice (Figures 3B and 3C). Adipose tissue insulin sensitivity

was assessed by measuring the percent decrease in plasma-free fatty acid concentration during the clamp study and was also normalized in the HFD BMT-Tlr4<sup>-/-</sup> mice (Figure 3D). Consistent with these changes in in vivo insulin sensitivity, we also observed increased Akt phosphorylation in insulin-stimulated liver and adipose tissue from the BMT-Tlr4<sup>-/-</sup> mice compared to BMT-WT controls (Figure 3F). Notably, the HFD-induced



**Figure 2. Insulin Tolerance Tests in BMT-*Tlr4*<sup>-/-</sup> Mice on HFD Show Normal Insulin Sensitivity**

(A) The insulin tolerance test (ITT) performed on bone marrow-transplanted mice reveals a significantly increased insulin sensitivity in BMT-*Tlr4*<sup>-/-</sup> mice fed a HFD compared to BMT-WT mice also fed HFD.

(B) The glucose tolerance test (GTT) reveals less-efficient glucose clearing over time in obese mice compared to normal weight control mice for either BMT group. (C and D) The partial correction of insulin levels in obese BMT-*Tlr4*<sup>-/-</sup> mice compared to BMT-WT mice. Area-under-curve analysis of insulin data from (C) shows a statistical difference between BMT-*Tlr4*<sup>-/-</sup> and BMT-WT mice both fed HFD.

\**p* < 0.05 for BMT-*Tlr4*<sup>-/-</sup> and \*\**p* < 0.01 for BMT-WT glucose levels, using Student's *t* test.

impairment in insulin-stimulated glucose disposal rate (IS-GDR) in BMT-WT, which primarily reflects skeletal muscle insulin sensitivity, was not prevented in BMT-*Tlr4*<sup>-/-</sup> mice (Figure 3E). Taken together, these data demonstrate that *Tlr4* deficiency in hematopoietic cells prevents HFD-induced glucose intolerance and insulin resistance, primarily via effects in the liver and adipose tissue.

The lipid content of liver and muscle lysates was also analyzed (Figure 3G). We observed reduced TAG and DAG concentrations in the livers of *Tlr4*<sup>-/-</sup> BMT mice with no change in muscle. These results are consistent with our findings of increased insulin sensitivity in liver, but not muscle, in the BMT-*Tlr4*<sup>-/-</sup> mice. We did not perform measures of lipogenesis or fat oxidation, and, although ketone body levels were the same between the two genotypes (Figure S4 available online), this is a relatively nonspecific assessment of fat oxidation. Therefore, we cannot be sure whether the decrease in hepatic TAGs and DAGs is due to increased fat oxidation or decreased lipogenesis.


#### Inflammatory Cytokine Signaling in Obese HFD BMT-*Tlr4*<sup>-/-</sup> Mice

Given that macrophages are the cell type with the highest surface expression of *Tlr4* and, as such, are potent sensors and effectors for *Tlr4*-mediated inflammatory responses, we

assessed various inflammatory markers in liver, adipose tissue, and skeletal muscle. Consistent with the MRI data in Figure 1G, HFD led to an increase in liver weights (Figure 4A). Because Kupffer cells express CD11b, we demonstrated that the liver macrophage population (Kupffer cells) was derived from the transplanted bone marrow by enriching for CD11b-positive cells using magnetic bead absorption according to the method of Seki et al. (Seki et al., 2007). Although peripheral blood mononuclear cells can also express CD11b, the number of these cells is very low in these liver tissues as determined by the q-PCR data showing normal *Tlr4* content in cells lacking CD11b. More importantly, CD11b-positive cells were almost completely devoid of *Tlr4* (Figure 4B), indicating near complete replacement of the recipient Kupffer cells with bone marrow donor-derived cells. This is in full agreement with the high-level reconstitution of donor-derived hematopoietic cells seen in the peripheral blood (Figure 1A).

In liver tissue, mRNA expression analyses of macrophage-specific immune activators such as IL-1 $\beta$  and F4/80 were significantly reduced by 60% and 30%, respectively, in HFD BMT-*Tlr4*<sup>-/-</sup> versus HFD BMT-WT mice (Figure 4C). Similarly, levels of other macrophage-expressed inflammatory genes, such as TNF- $\alpha$  and RANTES (Ccl5), were also significantly reduced (50% and 70%, respectively). Moreover, immune regulators





**Figure 3. The Hyperinsulinemic Euglycemic Clamp Test Shows that Obese BMT-*Tlr4*<sup>-/-</sup> Mice Have Normal Insulin Sensitivity of Hepatocytes and Adipocytes**

(A) Glucose infusion rates during clamp test of mice with the BMT-*Tlr4*<sup>-/-</sup> mice showing partial correction of insulin function as measured by partially restored glucose infusion rates ( $n = 8$ ).

(B) The hepatic glucose production (HGP) both at basal levels and during the clamp test. On HFD, HGP in the BMT-*Tlr4*<sup>-/-</sup> mice was not different from HGP on chow diet, whereas HFD led to an increase in HGP in the BMT-WT group.

(C) The percent of suppression of HGP.

(D) The percentage suppression of free fatty acid secretion from adipose tissue, with obese BMT-*Tlr4*<sup>-/-</sup> mice showing normalized adipocyte insulin sensitivity. (A–D)  $p < 0.05$ , using Student's  $t$  test.  $n > 8$ .

(E) The insulin-stimulated glucose disposal rate (IS-GDR) on NCD or HFD for the two genotypes.


(F) Western blot analyses of adipose and hepatic tissue for makers of insulin signaling. Analysis demonstrates the upregulated phosphorylated Akt in the adipose and liver of *Tlr4*<sup>-/-</sup> BMT mice compared to the WT BMT and all mice fed the HFD, suggesting increased insulin sensitivity. Data show representative wells with tubulin as a loading control.

(G) Lipid analyses of liver and muscle cell lysates from BMT mice. The triacylglycerol (TAG) and diacylglycerol (DAG) levels were determined via lipid extraction by organic solvents and separation via thin layer chromatography. Consistent with the in vivo BMT data, in which increased insulin sensitivity was seen in the *Tlr4*<sup>-/-</sup> mice, liver lysates from these mice showed reduced TAG and DAG. At least eight mice were analyzed per group, and the measurements were averaged from triplicate wells. Statistical analyses were performed on the samples using Student's  $t$  test.  $p < 0.1$ .

such as *Nos2*, *Cxcl1*, *Cxcl10*, and *Mmp9* tended toward reduced expression. As a control, the endothelial cell-specific marker VCAM1 showed no statistically significant change in level of expression between BMT-WT and BMT-*Tlr4*<sup>-/-</sup> mice. Complementing the changes in gene expression, the protein content in liver tissue of TNF- $\alpha$  and RANTES was also significantly reduced (Figures 4D and 4E) in BMT-*Tlr4*<sup>-/-</sup> mice. Western blot analysis of c-Jun N-terminal kinase 1 and 2 (JNK1/2) revealed that JNK signaling was also reduced in the livers and adipose tissues of HFD-fed BMT-*Tlr4*<sup>-/-</sup> versus BMT-WT mice (Figure S1). Because

TNF $\alpha$  and IL-6 stimulate JNK activity, which can interfere with IRS and insulin signaling, and tissue levels of these cytokines are reduced in the BMT-*Tlr4*<sup>-/-</sup> mice, these results are fully consistent with the enhanced insulin sensitivity in the BMT-*Tlr4*<sup>-/-</sup> groups. This connection between IL-6, JNK1, and insulin sensitivity is consistent with the work of Sabio et al. (Sabio et al., 2008).

In adipose tissue, the protein amounts of TNF- $\alpha$ , IL-6, and IL-12p70 were also significantly reduced (Figures 5A and S3). Because macrophages are an important source of TNF- $\alpha$  and IL-6 in adipose tissue (Weisberg et al., 2003; Xu et al., 2003), we



**Figure 4. Insulin Sensitivity in Hepatocytes of Obese Mice Correlates with Reduced Inflammatory Signaling of *Tlr4*<sup>-/-</sup> Hepatic Macrophages** (A and B) CD11b liver macrophages (predominantly Kupffer cells) play an important role in regulating inflammation in the liver. (A) and (B) show the increase in liver weight of HFD-fed mice compared to NCD mice and the near complete reconstitution of CD11b-positive cells of the *Tlr4*<sup>-/-</sup> genotype in the liver of obese mice following bone marrow transplantation. Homogenized liver tissue from bone marrow-transplanted mice was enriched for the macrophage-specific marker CD11b, and real-time PCR was performed to assay for wild-type *Tlr4* genomic DNA content. (C) The fold reductions of macrophage-specific and nonspecific proinflammatory cytokines, chemoattractants, and signaling molecules of BMT-*Tlr4*<sup>-/-</sup> mice compared to BMT-WT mice fed a HFD. (D and E) Levels of TNF-α and the chemoattractant RANTES via ELISA.

measured macrophage infiltration in adipose tissue from HFD BMT-WT and BMT-*Tlr4*<sup>-/-</sup> mice. Analysis of adipose tissue from HFD BMT-WT mice demonstrated increased staining with the macrophage-specific antibody, MAC2, as compared to NCD mice (Figure 5, compare 5C and 5E). Of interest, this was markedly reduced in BMT-*Tlr4*<sup>-/-</sup> mice (Figure 5F), as measured by the number of crown-like structures (macrophages) present in the extracellular space between adipocytes. These findings are consistent with the aforementioned reductions in gene expression and protein content of proinflammatory signaling molecules in both liver and adipose tissue.


#### Lentiviral Knockdown of *Tlr4* in HFD Mice

To verify the importance of hematopoietic *Tlr4* in mediating obesity-induced insulin resistance in mice, we utilized a novel approach, employing a lentiviral vector to knock down *Tlr4* in autologous hematopoietic stem cells. Bone marrow hematopoietic and progenitor cells from WT C57Bl6 donor mice were transduced in vitro with lentiviral vectors expressing a siRNA targeted against endogenous *Tlr4* (LV-si*Tlr4*) or a control vector. To ensure high-level transduction efficiency in the bone marrow cells, we included the marker gene GFP in both vectors. Transduced cells were then transplanted into irradiated C57Bl6 recip-

ients, and after 8 weeks for bone marrow reconstitution, bone marrow cells from these primary BMT mice were then sorted by flow cytometry for GFP expression. Using this approach, the GFP-positive cells represent the bone marrow cell population that was successfully and stably transduced with the LV-si*Tlr4* or control vector. We then transplanted these GFP-positive bone marrow cells into irradiated C57Bl6, secondary recipient mice. Endogenous levels of *Tlr4* in peripheral blood cells were knocked down by ~80% in LV-si*Tlr4* mice, as compared to control LV-GFP mice (Figure 6A). As expected, on HFD, both transplanted mouse groups gained a comparable amount of body weight (Figure 6B). On NCD, both the LV-si*Tlr4* mice and the control vector mice displayed insulin sensitivity during ITTs (Figure 6C). When the same mice were placed on HFD, the LV-sh*Tlr4* mice retained normal insulin sensitivity, whereas the control vector mice became insulin resistant (Figure 6D). These results confirm the role of hematopoietic *Tlr4* expression in obesity-induced insulin resistance.

#### DISCUSSION

Although recent evidence shows that chronic inflammation is a central contributing factor in the development of insulin



**Figure 5. Reduced Inflammatory Cell Recruitment to Adipose Tissue in BMT-Tlr4<sup>-/-</sup> Mice on HFD**

(A) Decreased expression of common proinflammatory cytokines in adipose tissue of BMT-Tlr4<sup>-/-</sup> mice compared to BMT-WT mice fed a HFD.

(B–F) Histological analysis of adipose tissue stained with MAC2 antibody for macrophage detection. Significantly increased macrophage infiltration between adipocytes is detectable and visually quantitated as crown-like structures with significant reductions in BMT-Tlr4<sup>-/-</sup> mice compared to BMT-WT mice fed HFD.

\*p < 0.05 for BMT-Tlr4<sup>-/-</sup> and p < 0.01 for BMT-WT, using Student's t test.


resistance in obesity, the pathway(s) that transduce the inflammatory signal in obesity are unclear. Here, we show that, in hematopoietic cells, knockout of Tlr4, which is a key receptor involved in activation of the innate immune/inflammatory response, prevents HFD/obesity-induced hyperinsulinemia, hyperglycemia, and abrogates insulin resistance in liver and adipose tissue. Importantly, the improved insulin action in adipose tissue and liver of these mice occurred in conjunction with reduced macrophage infiltration of adipose tissue, as well as reduced expression of proinflammatory cytokines, such as TNF- $\alpha$ , both in adipose tissue and liver. We further verified the importance of hematopoietic cell Tlr4 in the induction of insulin resistance by using a gene therapy approach to knock down Tlr4 in autologous hematopoietic stem cells. Considering that Tlr4 is a receptor for fatty acids, our results suggest that Tlr4 acts as an important transducer of the extracellular signal from fatty acids to activation of intracellular inflammatory pathways in hematopoietic cells (most likely macrophages), with subsequent release of proinflammatory cytokines that cause insulin resistance.

Chronic low-grade tissue inflammation has recently garnered considerable attention as a necessary contributor to insulin resistance in obesity. Tlrs play a critical role in activating the innate immune response and, consequently, have been implicated in the induction of insulin resistance in obesity. Tlr4 is an attractive candidate for linking innate immunity to insulin resistance because it is expressed in most cell types and Tlr4 is

also a receptor for fatty acids, which are increased in obesity (Lee et al., 2001, 2003). Indeed, several recent studies have demonstrated that mice with knockout of Tlr4 (Shi et al., 2006) or a loss-of-function mutation in Tlr4 (Tsukumo et al., 2007) are protected against fatty acid- and obesity-induced insulin resistance. However, because Tlr4 is expressed in many important insulin-responsive cell types (e.g., muscle, adipocytes, and hepatocytes), a limitation of these studies is that they do not specifically isolate the contribution of the innate immune system (e.g., macrophage, neutrophils, etc.) to changes in insulin sensitivity.

To address this and other questions, we used BMT to generate chimeric mice with knockout of Tlr4 specifically in hematopoietic cells. Because innate immune cells are derived from hematopoietic stem cells, our model results in the knockout of Tlr4 in macrophages, as well as in other hematopoietic cells. Of interest, our results demonstrate that BMT-Tlr4<sup>-/-</sup> mice are protected against HFD/obesity-induced hyperinsulinemia, insulin intolerance, and insulin resistance in adipose tissue and the liver. These results are in line with recent studies in which we found that myeloid-specific knockdown of JNK1 (which is a downstream target of Tlr4 signaling) and IKK improve insulin sensitivity in HFD-fed mice.

Two previous studies have examined the issue of insulin resistance in mice in which Tlr4 is either knocked out or disabled (Shi et al., 2006; Tsukumo et al., 2007). In the paper by Shi et al. (Shi et al., 2006), the authors show that the Tlr4 knockout protects animals from the effects of acute lipid infusions to cause insulin resistance; however, the tissues that are responsible for this systemic effect could not be specified. This finding during acute lipid infusions did not translate that well into the setting of chronic HFD. Thus, they found that the Tlr4 deletion had no effect on body weight or insulin sensitivity in HFD-fed male mice but did lead to increased obesity with insulin sensitivity in females. In contrast, Tsukumo et al. (Tsukumo et al., 2007) studied mice with a loss-of-function Tlr4 mutation and found that male animals gained less body weight than controls on



**Figure 6. Lentiviral Vector-Mediated Knockdown of Tlr4 in a Hematopoietic Stem Cell Gene Therapy Setting Maintains Insulin Sensitivity in HFD Mice**

(A) Lentiviral vector driving expression of siRNA targeted against Tlr4 in bone marrow-transplanted mice of transduced and sorted hematopoietic stem cells yields partial but significant knockdown of Tlr4 expression in peripheral blood mononuclear cells of transplanted mice as determined by real-time PCR.  $n = 3$ .

(B) Average weights of mice fed either a HFD or a NCD.

(C and D) ITT was performed at 8 weeks posttransplant with LV-siTlr4 and control vector-transduced bone marrow mice receiving NCD (C) or HFD (D).

HFD and became less insulin resistant. However, in the setting of a lean and insulin-sensitive phenotype, it is not clear whether it is the leanness of the mouse or the knockout of Tlr4, per se, that causes the insulin sensitivity, and the tissue type that is responsible for the phenotype could not be determined. Because our chimeric mice express Tlr4 deficiency only in bone marrow-derived hematopoietic cells, both control and knockout mouse models gained an equal amount of weight on HFD and had equal expansion of both subcutaneous and visceral adipose depots. Thus, differences in adiposity between our two groups (BMT-WT and BMT-Tlr4<sup>-/-</sup>) are not a confounding factor, making it possible to ascertain the contribution of hematopoietic cell Tlr4 signaling to insulin sensitivity. It is not clear why the Shi et al. and Tsukumo et al. studies are so different from each other, but perhaps it is due to the fact that one group studied Tlr4 null animals (Shi et al., 2006), whereas the other studied a mouse strain carrying a loss-of-function mutation in the Tlr4 receptor (Tsukumo et al., 2007). Of course, other strain differences may also be contributing factors. Clearly, the animal model that we used is much different because we employed adoptive transfer to generate chimeric animals all on the same background in which the Tlr4 depletion is only carried in hematopoietic-derived cells with normal Tlr4 in all other tissues.

It is of interest that, although we found substantial effects of the hematopoietic Tlr4 knockout to cause systemic insulin sensitivity, these effects were primarily manifested in liver and adipose

tissue. With respect to skeletal muscle, we did not observe changes in the insulin-stimulated in vivo glucose disposal rate, and because 70%–80% of in vivo insulin-stimulated glucose disposal is into skeletal muscle, this implies no major changes in skeletal muscle insulin sensitivity. It is well known that, on HFD, large increases in macrophage numbers occur in adipose tissue and that, in the liver, Kupffer cell inflammatory activation state is enhanced and the number of Kupffer cells may also be increased. On the other hand, there are relatively few macrophages that appear in skeletal muscle on HFD, and these cells are mostly present in intermuscular adipose deposits. Because inflammatory markers were markedly decreased in liver and adipose tissue of the BMT-Tlr4<sup>-/-</sup> mice, the data indicate that Tlr4 expression in hematopoietic-derived cells is an important control point for HFD-induced inflammation in adipose tissue in liver. In skeletal muscle, it is possible that the Tlr4 on the muscle cell itself plays the major role in detecting lipid signals in the setting of HFD-induced skeletal muscle insulin resistance. Indeed, Tsukumo et al. provide evidence for this hypothesis because they have directly shown that, when studied ex vivo, Tlr4 knockout muscle is protected from fatty acid-induced insulin resistance. This is consistent with our own results in which we show that deletion of hematopoietic cell Tlr4 is sufficient to cause a systemic insulin-sensitive phenotype but that this was primarily manifested in liver and adipose tissue and not muscle.



Tlr4 in macrophages is necessary for activation of inflammatory pathways by fatty acids or lipopolysaccharides (LPS). Knockdown of Tlr2 and/or Tlr4 in macrophage cells attenuates fatty acid-induced activation of Jnk1 and abrogates TNF- $\alpha$  secretion into the media. In fact, JNK1 is an obligatory component for the ability of fatty acids and Tlr4 to activate inflammatory pathways and to increase TNF- $\alpha$  secretion (Nguyen et al., 2007). In support of these findings, we found that the expression of several proinflammatory cytokines, namely, IL-6, TNF- $\alpha$ , and IL-12 p70, was markedly reduced in adipose tissue from BMT-*Tlr4*<sup>-/-</sup> mice on HFD. It is likely that the reduced expression of TNF- $\alpha$  is directly related to the reduced macrophage infiltration, as macrophages are the primary source of TNF- $\alpha$  in obese adipose tissue (Weisberg et al., 2003; Xu et al., 2003). It is notable that IL-12 p70 was reduced in our mice because IL-12 is important for the transition of naive T cells into Th1 cells (Hsieh et al., 1993). This is relevant to our studies because the main targets of Th1 cells are macrophages, whereby Th1 cells act to induce a macrophage proinflammatory state. Thus, we hypothesize that Tlr4 is an obligate receptor for the transduction of an obesity-derived signal (i.e., increased fatty acids) to macrophages. In turn, activation of inflammation via macrophage Tlr4 potentiates recruitment of additional cells to adipose tissue, with subsequent polarization to a proinflammatory state. This feed-forward process is likely exacerbated by the fact that Tlr4 expression is increased in macrophages in obese adipose tissue (Nguyen et al., 2007). Consistent with this, insulin's effect to suppress circulating FFA levels was much greater in the BMT-*Tlr4*<sup>-/-</sup> mice, indicative of improved adipose insulin action.

In the liver, macrophages are present in the form of Kupffer cells. Because Kupffer cells are bone marrow derived, our model allows us to determine the effect of Tlr4 in Kupffer cells on induction of inflammation (and insulin resistance) in the liver of obese animals. Similar to results in adipose tissue, we found that the expression of various proinflammatory markers was markedly reduced in the liver of BMT-*Tlr4*<sup>-/-</sup> mice. In fact, the HFD-induced increase in TNF- $\alpha$  and RANTES in liver was completely reversed in BMT-*Tlr4*<sup>-/-</sup> mice. In parallel with this decrease in inflammation, the ability of insulin to suppress HGP in BMT-*Tlr4*<sup>-/-</sup> mice was normalized to values seen in chow-fed mice. These results suggest that activation of inflammatory pathways in immune cells in the liver is necessary for induction of hepatic insulin resistance on HFD.

We extended these findings by demonstrating that transplantation of mice with bone marrow containing lentiviral-driven siRNA knockdown of Tlr4 leads to improved insulin sensitivity on HFD. Of interest, this occurred despite the fact that we did not achieve as high a level of knockdown as seen in the BMT-*Tlr4*<sup>-/-</sup> mice (>95% versus 80% knockdown for BMT-*Tlr4*<sup>-/-</sup> and LV-si*Tlr4*, respectively), suggesting that complete knockdown of Tlr4 is not necessary in order for beneficial metabolic effects to occur.

During the review of this manuscript, Coenen et al. (Coenen et al., 2009) published a paper using the BMT-*Tlr4*<sup>-/-</sup> approach and reported a decrease in ATM content with reduced markers of adipose tissue inflammation on HFD in the KO mice. They also found a decrease in atherosclerosis in the KO mice, but no changes in glucose homeostasis. However, this study consisted of only female mice of the LDL KO background, and

they were nonobese Agouti animals and, thus, markedly different than those in the current study.

In summary, we have demonstrated that knockout of Tlr4 signaling in macrophages reverses insulin resistance in adipose tissue and liver in HFD-fed obese mice. This protection occurs in parallel with a marked reduction in macrophage infiltration in adipose tissue and reduced inflammatory markers in adipose and liver. Altogether, these data indicate the importance of innate immunity and hematopoietic-derived cells, particularly macrophages and Kupffer cells, in the induction of insulin resistance in obesity. Our data also identify Tlr4 in hematopoietic-derived cells as a potential target for the therapeutic treatment of insulin resistance.

## EXPERIMENTAL PROCEDURES

### Bone Marrow Transplantation

Murine total bone marrow hematopoietic progenitor donor cells were harvested from WT or *Tlr4*<sup>lps-del</sup> C57B10 mice (Jackson Laboratories, Bar Harbor, ME) and were transplanted via tail vein injection into lethally irradiated C57B16J mice (1100 rads; Cobalt-60 source) with a minimum cell dose of 10<sup>6</sup> mononuclear cells, or 100,000 lineage-depleted cells per mouse. Transplanted mice were housed in microisolator housing for 6 weeks prior to challenge with HFD and subsequent insulin sensitivity analyses. For experiments in which lentiviral vectors were used to knock down Tlr4, bone marrow from wild-type CD45.1 mice (backcrossed to C57B16J mice; Jackson Laboratories) was lineage depleted for hematopoietic progenitor cell enrichment (as per manufacturer's instruction, Stem Cell Technologies, Vancouver, BC). Transduction of the progenitor and stem cells was performed as described below.

### Lentiviral Vectors

The third-generation lentiviral vectors used in these studies have been described but, in brief, contain the self-inactivating deletion and an internal CMV promoter driving the marker gene GFP (Dull et al., 1998). The siRNA cassette directed against Tlr4 and driven by human H1 Pol III promoter was placed upstream of the CMV promoter (cloning details provided upon request). Lentiviral vector supernatants were prepared as previously described (Miyoshi et al., 1998).

### Transduction

The protocol for efficient transduction of lineage-depleted hematopoietic stem cells and progenitors has been previously described (Woods et al., 2006). In brief, transduction conditions involved 2 days of prestimulation in serum-free expansion medium (SFEM) with 50 ng/ml of each stem cell factor, thrombopoietin, and flt-3 ligand (Stem Cell Technologies, Vancouver, BC), followed by a high multiplicity of infection transduction of blood cells by pelleting up to 500,000 cells and resuspending ~30–100  $\mu$ l of concentrated virus with a titer greater than 10<sup>9</sup> HeLaTU/ml and the volume of virus adjusted to ensure a minimum of 100 infectious units per cell. Incubation was for 1 hr, followed by addition of 150  $\mu$ l of SFEM medium and cytokines overnight. A second hit was then performed using an additional 30–50  $\mu$ l of high titer virus directly to the cells in medium and incubated an additional night. All incubations are performed at 37°C with 5% CO<sub>2</sub>. Expansion during 4 day transduction was ~2- to 3-fold.

### Metabolic Studies

Insulin tolerance tests (ITT) were performed pre- and postdiet and following Tlr4 knockdown in all groups of animals. ITT testing allowed us to determine the effectiveness of insulin to reduce fasting glucose levels. In brief, mice were fasted 6 hr, and blood glucose concentrations were assessed before the injection of 0.5 U/kg insulin (intraperitoneal injection) and then 10, 15, 20, 30, 45, 60, and 90 min following injection. At each time point, a 5  $\mu$ l blood sample was collected via tail nick, and glucose was assessed with LifeScan OneTouch glucose monitoring system. At 1 week later, the same group of animals was subjected to a glucose tolerance test (GTT). Here, animals were fasted 6 hr, and blood glucose concentrations were assessed before and

10, 15, 20, 30, 45, 60, and 90 min after the injection of 1g/kg 50% dextrose (454 mg/ml).

#### Hyperinsulinemic-Euglycemic Clamp

Hyperinsulinemic-euglycemic clamps were conducted to determine insulin-stimulated glucose disposal rate (IS-GDR) and the inhibitory effect of insulin on hepatic glucose production (HGP). In brief, mice were anesthetized with ketamine (80 mg/kg), acepromazine (0.5 mg/kg), and xylazine (16 mg/kg) via IP injection. The jugular vein was cleared of surrounding tissue, and two micro-urethane catheters (Type MRE-025) were advanced ~1 cm into the vessel and secured with 4-0 silk suture. The catheters were tunneled to the midscapular region and externalized. The skin was closed with 6-0 suture, and the catheters were secured within silastic tubing (0.078" ID × 0.125" OD) that had been externalized and secured to the skin with 6-0 silk suture. The mice were allowed to recover for 5 days before undergoing the clamp protocol. Following a 6 hr fast, blood glucose was assessed via tail nick, body mass was measured, and the mice were placed in a Lucite restrainer (Bintree Scientific, Bintree, MA). Once in the restrainer, ~75  $\mu$ l of whole blood was collected for the assessment of plasma insulin and free fatty acids (at  $t = -60$  min). Equilibrating tracer solution (41.6  $\mu$ Ci  $^3$ H/ml at 2  $\mu$ l/min) was infused intravenously for 60 min. At the end of the equilibration period ( $t = 0$  min),  $2 \times 15 \mu$ l of whole blood was collected, and blood was deproteinized for the assessment of tracer specific activity and basal glucose disposal rate. Following the equilibration period, a cocktail containing 8% BSA, insulin, and tracer was infused at a constant rate (6.0 mU/kg/min and 41.6  $\mu$ Ci/ml at 2.0  $\mu$ l/min) along with a variable glucose infusion (50% dextrose, 454 mg/ml). Blood glucose was assessed every 10 min for determination of glucose infusion rate. Glucose infusion rate was adjusted until steady-state blood glucose (120 mg/dl,  $\pm 5$  mg/dl) was achieved. The clamp was terminated when steady-state conditions were maintained for  $\geq 30$  min (~120 min), at which time  $2 \times 15 \mu$ l of blood was collected for assessment of tracer-specific activity and insulin-stimulated glucose disposal rate ( $t = \sim 120$  min). At the end of the clamp period, the mouse were exsanguinated by cardiac puncture ( $\geq 1$  ml, whole blood collected), and tissues were harvested, mass recorded, and preserved as required for future analysis.

#### Tissue Collection and Analysis

At the end of each clamp study, muscle, liver, and fat tissues were harvested for measuring of the mRNA and protein content of insulin-signaling molecules and inflammatory-signaling molecules. Real-time RT-PCR was performed using ABI systems 9600 thermal cycler (primers sequences available upon request). MRI analyses, including adipose volume determinations, were performed using UCSD functional MRI core facility using the 7T system (21 cm bore, Bruker Avance II console). Adipose tissue immunohistochemistry was performed via cryostat sectioning followed by staining with Mac2 antibody (BD Pharmingen) with analysis of crown-like structures as defined previously by Murano et al. (Murano et al., 2008). Kupffer cell-enriched fractions were prepared from collagenase and pronase digested livers using CD11b magnetic beads (Seki et al., 2007).

The triacylglycerol (TAG) and diacylglycerol (DAG) levels in liver and muscle cell lysates were determined using 50–100 mg of tissue, subjected to lipid extraction by organic solvents as previously described by Bligh and Dyer (1959) and Folch et al. (1957). The organic solvent layer containing extracted lipids was dried and dissolved in 0.1 ml chloroform. TAG and DAG were separated by thin layer chromatography (TLC) and extracted from silica gel by chloroform/methanol. For TAG determination, solvent was evaporated and TAG was resuspended by sonication in TBS containing 0.1% NP-40. The amount of TAG was determined by a commercial kit from WAKO Diagnostic, which measures glycerol level released after hydrolysis of TAG by a lipase. For DAG determination, evaporated lipids were saponified by 1 M KOH for 1 hr at 55°C, and the mixture was neutralized by 2N HCl. Glycerol level released by hydrolysis of DAG was measured by the same WAKO kit above.

Westerns were performed using 4%–12% SDS-PAGE acrylamide gels (Invitrogen, CA). The phospho-JNK antibody that was used targets the threonine 308 amino acid residue. All antibodies were purchased from Cell Signaling Technology (MA).

BioPanel analysis of inflammatory markers in serum from BMT mice for Figure S2 (plasma insulin, leptin, resistin, MCP-1, and plasminogen activator

inhibitor [PAI-1]) were measured with a multiplex adipokine assay kit (MADPK-71K, Millipore) according to the instructions of the manufacturer. The multiplex adipokine assays were performed by using a Luminex 200 MAP system (Luminex Technology).

#### SUPPLEMENTAL DATA

Supplemental Data include four figures and can be found with this article online at [http://www.cell.com/cell-metabolism/supplemental/S1550-4131\(09\)00294-0](http://www.cell.com/cell-metabolism/supplemental/S1550-4131(09)00294-0).

#### ACKNOWLEDGMENTS

We thank Anh-Khoi Nguyen and Arezou Amidi for their help with animal maintenance and assistance with ITTs and GTTs. We would also like to thank Gabriela Estepa for assistance with molecular biology techniques. Plasma adipokines were assayed by the University of California at Los Angeles DERC Inflammation Core (DK-063491-06). This work was supported by grants from the National Institutes of Health grants DK033651, DK074868, and T32 DK 007494, as well as UC Discovery BioStar grant bio06-10567. This research was also supported by the Eunice Kennedy Shriver NICHD/NIH through cooperative agreement of U54 HD 012303-25 as part of the specialized Cooperative Centers Program in Reproduction and Infertility Research. I.M.V. is an American Cancer Society Professor of Molecular Biology and is supported, in part, by grants from the NIH, Leducq Foundation, Lustgarten Foundation, Ellison Medical Foundation, and the H.N. and Frances C. Berger Foundation. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Received: October 26, 2008

Revised: May 29, 2009

Accepted: September 25, 2009

Published: November 3, 2009

#### REFERENCES

- Aderem, A., and Ulevitch, R.J. (2000). Toll-like receptors in the induction of the innate immune response. *Nature* 406, 782–787.
- Arkan, M.C., Hevener, A.L., Greten, F.R., Maeda, S., Li, Z.W., Long, J.M., Wynshaw-Boris, A., Poli, G., Olefsky, J., and Karin, M. (2005). IKK-beta links inflammation to obesity-induced insulin resistance. *Nat. Med.* 11, 191–198.
- Bligh, E.G., and Dyer, W.J. (1959). A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* 37, 911–917.
- Coenen, K.R., Gruen, M.L., Lee-Young, R.S., Puglisi, M.J., Wasserman, D.H., and Hasty, A.H. (2009). Impact of macrophage toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice. *Diabetologia* 52, 318–328.
- Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M., Trono, D., and Naldini, L. (1998). A third-generation lentivirus vector with a conditional packaging system. *J. Virol.* 72, 8463–8471.
- Facchini, F.S., Hua, N., Abbasi, F., and Reaven, G.M. (2001). Insulin resistance as a predictor of age-related diseases. *J. Clin. Endocrinol. Metab.* 86, 3574–3578.
- Folch, J., Lees, M., and Sloane Stanley, G.H. (1957). A simple method for the isolation and purification of total lipids from animal tissues. *J. Biol. Chem.* 226, 497–509.
- Horowitz, J.F., Braudy, R.J., Martin, W.H., III, and Klein, S. (1999). Endurance exercise training does not alter lipolytic or adipose tissue blood flow sensitivity to epinephrine. *Am. J. Physiol.* 277, E325–E331.
- Hsieh, C.S., Macatonia, S.E., Tripp, C.S., Wolf, S.F., O'Garra, A., and Murphy, K.M. (1993). Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. *Science* 260, 547–549.
- Jensen, M.D., Haymond, M.W., Rizza, R.A., Cryer, P.E., and Miles, J.M. (1989). Influence of body fat distribution on free fatty acid metabolism in obesity. *J. Clin. Invest.* 83, 1168–1173.

- Lee, J.Y., Sohn, K.H., Rhee, S.H., and Hwang, D. (2001). Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. *J. Biol. Chem.* 276, 16683–16689.
- Lee, J.Y., Ye, J., Gao, Z., Youn, H.S., Lee, W.H., Zhao, L., Sizemore, N., and Hwang, D.H. (2003). Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. *J. Biol. Chem.* 278, 37041–37051.
- Miyoshi, H., Blomer, U., Takahashi, M., Gage, F.H., and Verma, I.M. (1998). Development of a self-inactivating lentivirus vector. *J. Virol.* 72, 8150–8157.
- Murano, I., Barbatelli, G., Parisani, V., Latini, C., Muzzonigro, G., Castellucci, M., and Cinti, S. (2008). Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. *J. Lipid Res.* 49, 1562–1568.
- Nguyen, M.T., Favelyukis, S., Nguyen, A.K., Reichart, D., Scott, P.A., Jenn, A., Liu-Bryan, R., Glass, C.K., Neels, J.G., and Olefsky, J.M. (2007). A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. *J. Biol. Chem.* 282, 35279–35292.
- Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* 282, 2085–2088.
- Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J.Y., Ko, H.J., Barrett, T., Kim, J.K., and Davis, R.J. (2008). A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science* 322, 1539–1543.
- Seki, E., De Minicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A., and Schwabe, R.F. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat. Med.* 13, 1324–1332.
- Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., and Flier, J.S. (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. *J. Clin. Invest.* 116, 3015–3025.
- Solinas, G., Vilcu, C., Neels, J.G., Bandyopadhyay, G.K., Luo, J.L., Naugler, W., Grivennikov, S., Wynshaw-Boris, A., Scadeng, M., Olefsky, J.M., and Karin, M. (2007). JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. *Cell Metab.* 6, 386–397.
- Tsukumo, D.M., Carvalho-Filho, M.A., Carvalheira, J.B., Prada, P.O., Hirabara, S.M., Schenka, A.A., Araujo, E.P., Vassallo, J., Curi, R., Velloso, L.A., and Saad, M.J. (2007). Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. *Diabetes* 56, 1986–1998.
- Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W., Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* 112, 1796–1808.
- Wolowczuk, I., Verwaerde, C., Viltart, O., Delanoye, A., Delacre, M., Pot, B., and Grangette, C. (2008). Feeding our immune system: impact on metabolism. *Clin. Dev. Immunol.* 2008, 639803.
- Woods, N.B., Bottero, V., Schmidt, M., von Kalle, C., and Verma, I.M. (2006). Gene therapy: therapeutic gene causing lymphoma. *Nature* 440, 1123.
- Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J. Clin. Invest.* 112, 1821–1830.